Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-50
SponsorUniversity of Colorado, Denver

About this trial

Down syndrome (DS), the most common genetic cause of intellectual disability, is associated with widespread organ dysfunction, including abnormalities in the autonomic nervous system (ANS). The ANS regulates critical functions such as heart rate (HR) and blood pressure (BP), both essential for maintaining homeostasis and supporting physical activity. Individuals with DS often exhibit blunted HR responses to exercise-typically \~30 beats per minute below expected levels-suggesting reduced sympathetic nervous system (SNS) activity. The SNS governs rapid changes in HR and BP during stress by releasing catecholamines: epinephrine (from the adrenal medulla) and norepinephrine (from sympathetic nerve endings). Despite its importance, SNS function has not been comprehensively assessed among individuals with DS.

This study addresses a critical knowledge gap by evaluating SNS responses to physiological stressors in individuals with DS. The investigators will measure beat-to-beat HR and BP, along with plasma catecholamine levels, in response to sympathetic activation, comparing individuals with DS to age- and sex-matched controls. Understanding the mechanisms of SNS dysfunction in DS is vital, as it likely underlies reduced exercise capacity and contributes to broader clinical challenges. These insights may guide targeted interventions to improve cardiovascular function, physical capacity, and overall quality of life in this understudied population.

Eligibility criteria

Qualifiers

18-50 yrs old and apparently healthy individuals

Ability to understand the study and give assent to participate

Has a study partner who can attend all visits for the individuals with DS, and answer questionnaires, provide consent when necessary

Corrected or non-existent congenital heart disease

Disqualifiers

Hypertension (resting systolic blood pressure [SBP] ≥140 and/or diastolic blood pressure [DBP] ≥90 mmHg) this includes those on medications to treat hypertension

Hypotension (resting BP of <90/60 mmHg)

Cancer in the last six months

Any heart-rate-altering medications or any other medication that may modify metabolic responses

Trial design

Treatments tested in this trial

  • Fear Response
  • Cold Stress
  • Pain Response
  • Caffeine
  • 12-Hour Fast
  • Maximal Dynamic Exercise

Treatment groups

200 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Colorado, Denver

Lead sponsor

National Institute on Aging (NIA)

Collaborator

Linda Crnic Institute for Down Syndrome

Collaborator

GLOBAL Down Syndrome Foundation

Collaborator

University of Colorado Colorado Clinical and Translational Sciences Institute

Collaborator